Proteasome inhibition therapies in childhood cancer

Leukemia

Volumn 22, Issue 4, 2008, Pages 883-884

  Zaman, F ^a   Fadeel, B ^b   Savendahl L ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INDUCING FACTOR; BORTEZOMIB; MG 262; PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; BONE DENSITY; BONE DISEASE; BONE GROWTH; BONE MATURATION; CARTILAGE CELL; CELL DIFFERENTIATION; CELL LINE; CELL POPULATION; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; EX VIVO STUDY; GROWTH DISORDER; GROWTH PLATE; GROWTH RETARDATION; HUMAN; HUMAN CELL; LETTER; METATARSAL BONE; MOUSE; MOUSE STRAIN; MULTIPLE MYELOMA; NONHUMAN; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; RAT; SOLID TUMOR; TISSUE CULTURE; UPREGULATION;

EID: 42349087223     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404997     Document Type: Letter

References (6)

1. Terpos E, Dimopoulos MA, Sezer O. The effect of novel antimyeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007; 21: 1875-1884.
2. Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007; 110: 334-338.
3. Zaman F, Menendez-Benito V, Eriksson E, Chagin AS, Takigawa M, Fadeel B et al. Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice. Cancer Res 2007; 67: 10078-10086.
4. Schrier L, Ferns SP, Barnes KM, Emons JA, Newman EI, Nilsson O et al Depletion of resting zone chondrocytes during growth plate senescence. J Endocrinol 2006; 189: 27-36.
5. Blaney SM, Bernstein M, Neville K, Ginsberg J, Kitchen B, Horton T et al. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: A Children's Oncology Group study (ADVL0015). J Clin Oncol 2004; 22: 4804-4809.
6. Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, Adamson PC et al. Phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: A Children's Oncology Group study. Clin Cancer Res 2007; 13: 1516-1522.